In summary, by integrating our bioinformatic, histopathologic and radiologic findings with our human cerebral organoid model of meningioma, we identify CDH2 and PTPRZ1 as genes that are enriched in high ADC regions that drive meningioma cell proliferation and tumorigenesis, and represent novel targets for molecular therapy to treat meningioma patients. Here, CDH2 is linked to meningioma.